Almac Group has reported a £17 million rise in turnover from £531 million to £548 million for 2017-18. Pre-tax profits were recorded at £27 million whilst average employee figures increased by 8% from 4,407 to 4,798 for the same period. The figures were recorded in Almac’s annual report with its results for the year ending 30 September 2018.
Throughout this period, the global contract pharmaceutical development and manufacturing organisation made a number of significant investments including further development of its European Campus in Dundalk, Ireland, a multimillion pound expansion of capacity at its site in Athlone in addition to further investment at its existing facilities in the UK, US and Asia.
Global expansion continued with the acquisition of Athlone-based, BioClin Laboratories, which significantly increased its global analytical services capabilities.
Delivering upon its outreach strategy, Almac also has committed to invest over £1 million through a partnership agreement with W5 in Belfast, Ireland’s interactive science centre, to enhance STEM (Science, Technology, Engineering & Maths) knowledge and understanding among the next generation.
Alan Armstrong, Group CEO, commented: “Almac experienced yet another strong year in 2018 with our key financial and global employee metrics increasing. We made significant progress on our ambitious growth strategy with the acquisition of BioClin Laboratories and the continued investment in our existing global facilities, in addition to increased headcount. With 100% of our profits reinvested into the business, we will continue to innovate and improve our wide range of services and products to ensure we provide the premium solutions our global client base relies on.”
